Index

Note: Page numbers of article titles are in boldface type.

A
Absorption
impaired, 181
Acetaminophen
liver injury related to, 172–173
Activity
defined, 114
Adenoma(s)
hepatocellular, 38
Adipokine(s)
from visceral fat
obesity effects on, 44–45
Adiponectin
polymorphisms in
in obesity-associated NAFLD, 259–260
Adipose tissue
as endocrine organ, 41–58
introduction, 41–42
visceral fat composition, 42–44
Alcohol
HCC effects of, 160
Alcoholic liver disease (ALD)
epidemiology of, 157
mortality related to
obesity and metabolic syndrome effects on, 159–160
obesity and metabolic syndrome effects on, 157–163
clinical management of, 160–162
future directions in, 160–162
mortality-related, 159–160
progression-related, 158–159
progression of
diabetes mellitus effects on, 160
obesity effects on, 158–159
spectrum of, 158
ALD. See Alcoholic liver disease (ALD)
Anesthesia/anesthetics
liver injury related to, 173
Antibiotics
in obesity-associated NAFLD, 66–67
Antioxidants
in NAFLD management, 77–80, 101–105
Apolipoprotein C-III
  polymorphisms in
    in obesity-associated NAFLD, 254

Atherosclerosis
  surrogate markers of
    NAFLD and, 234–235

B

Bariatric-metabolic (BM) surgery
  benefits of, 133
    laparoscopic
      in NAFLD management in morbidly obese patients, 130–133
      in NAFLD management in morbidly obese patients, 133–141
        with cirrhosis, 140–141
        established therapy with, 141
        procedure-specific concerns, 140
        studies examining paired liver biopsies, 136–139
  in obesity management, 13–14

Bariatric surgery
  in obesity management, 13–14

Beta-adrenergic receptor
  polymorphisms in
    in obesity-associated NAFLD, 256–257

Bile acids and derivatives
  in NAFLD management, 80–81

BM surgery. See Bariatric-metabolic (BM) surgery

C

Cancer(s)
  liver. See Hepatocellular carcinoma (HCC); Liver cancer; specific types, e.g.,
    Hepatocellular adenoma

Cardiovascular diseases
  NAFLD and
    interactions between, 233–248. See also Nonalcoholic fatty liver disease (NAFLD),
      cardiovascular diseases and, interactions between

Children
  liver disease in, 219–231
    treatment of, 223–227
  NAFLD in
    evaluation of, 221–223
  nutrition in, 219–231
    management of, 223–227
  obesity in, 219–231
    comorbid conditions, 220
    epidemiology of, 219–220
    evaluation of, 220–221
    NAFLD with, 220
    treatment of, 223–227

Chronic liver disease (CLD)
  HCC in
    obesity as risk factor for, 197
introduction, 179–180
malnutrition and, 206–209
nutrition in, 179–190, 205–218
  assessment of, 181–184
  introduction, 179–180, 205–206
  recommendations for, 184–187
obesity effects on, 209–210
  introduction, 205–206
poor nutritional status in
  management strategies for, 211–212
Cirrhosis
  BM surgery in patients with, 140–141
  cryptogenic, 37–38
  malnutrition in
    pathogenesis of, 180
    prevalence of, 180
nutrition in, 179–190
  assessment of, 181–184
  recommendations for, 184–187
obesity and, 8
Cryptogenic cirrhosis, 37–38
Cytokine(s)
  from visceral fat
    obesity effects on, 44–45

D
Decompensated liver disease
  obesity and, 8
Diabetes mellitus
  ALD progression effects of, 160
Diet
  exercise and
    in NAFLD management, 119–120
    in NAFLD management, 91–112. See also Nonalcoholic fatty liver disease (NAFLD), management of, diet and nutritional intervention in
Digestion
  impaired, 181
DILI. See Drug-induced liver injury (DILI)
Drug(s)
  in obesity management, 10–13. See also specific drugs
Drug-induced liver injury (DILI)
  described, 171–173
  idiosyncratic, 172
  intrinsic, 172–173
  obesity and metabolic syndrome effects on, 165–178

E
Endocannabinoids
  in NAFLD management, 83
Endocrine organ
  adipose tissue as, 41–58. See also Adipose tissue, as endocrine organ

Exercise
  defined, 115
  
  diet and
    in NAFLD management, 119–120
    in functional status improvement of patients with NAFLD, 113–127. See also Nonalcoholic fatty liver disease (NAFLD), functional status of patients with, exercise in optimization of

Ezetimibe
  in NAFLD management, 78

F

Fat(s)
  visceral
    adipokines and cytokines derived from
      obesity effects on, 44–45
  
  Fatty acid transport protein 5
    polymorphisms in
      in obesity-associated NAFLD, 256

Fiber
  in NAFLD management, 101–105

Fibrate(s)
  in NAFLD management, 78–79

Framingham risk score (FRS)
  in predicting cardiovascular disease in NAFLD patients, 243

Fructose
  GI and, 98–99

Function
  defined, 114

G

Genetic association studies
  in obesity-associated NAFLD, 251

GI. See Glycemic index (GI)

Giltazones
  in NAFLD management, 76–77

Glycemic index (GI)
  defined, 98
    fructose and, 98–99

Gut microbiota
  NAFLD and, 62–67
    obesity and, 60–62

H

HBV. See Hepatitis B virus (HBV)

HCC. See Hepatocellular carcinoma (HCC)

HCV. See Hepatitis C virus (HCV)
Hepatitis B virus (HBV)
  described, 165–166
  obesity and metabolic syndrome effects on, 165–178
  steatosis in patients with
    molecular mechanisms and factors associated with, 167–168
    prevalence and determinants of, 166–167
Hepatitis C virus (HCV)
  insulin resistance and, 149–150
  obesity and metabolic syndrome effects on, 7, 147–156
    insulin resistance, 149–150
    introduction, 147–148
    significance of, 151–152
    steatosis, 150
    terminology related to, 148–149
Hepatocellular adenoma, 38
Hepatocellular carcinoma (HCC), 38
  alcohol effects on, 160
    in noncirrhotic liver with NAFLD, 195–197
  obesity and, 7–8, 160, 192–193
    carcinogenesis mechanisms, 197–200
    in CLD of different etiology, 197
    in NAFLD, 194–195
Hepatoprotective agents
  in NAFLD management, 77–80
Hepadn
  obesity effects on, 45–48
H1F1
  obesity effects on, 48
High-protein diet
  in NAFLD management, 100–101
Hormone imbalances
  obesity and, 51–52
Human hemochromatosis protein
  polymorphisms in
    in obesity-associated NAFLD, 260–261
Hypoxia
  obesity effects on, 45–49

I
Incretin mimetics
  in NAFLD management, 82
Inflammation
  obesity effects on, 49–50
Insulin resistance
  HCV and, 149–150
  obesity effects on, 50–51
Insulin sensitizers
  in NAFLD management, 74–77
    glistazones, 76–77
    metformin, 74–76
L

Laparoscopic BM surgery
  in NAFLD management in morbidly obese patients, 130–133

Leptin receptor
  polymorphisms in
    in obesity-associated NAFLD, 259

Lifestyle modifications
  in obesity management, 8–10

Lipid(s)
  described, 99–100
  metabolism of
    polymorphisms in genes influencing
      in obesity-associated NAFLD, 254–257

Lipid-lowering drugs
  in NAFLD management, 77–80

Lipin1
  polymorphisms in
    in obesity-associated NAFLD, 255–256

Liver
  histology of
    obesity effects on, 33–40
  noncirrhotic
    HCC and
      in NAFLD, 195–197
  normal, 33–34
  in nutrient metabolism, 206
  in weight regulation, 6

Liver cancer. See also Hepatocellular carcinoma (HCC); specific types, e.g., Hepatocellular adenoma
  obesity and, 191–203
    HCC, 192–193
    introduction, 191–192

Liver disease. See also specific types
  alcoholic. See Alcoholic liver disease (ALD)
    in children, 219–231
  obesity and, 1–18. See also Obesity, liver disease related to

Low-carbohydrate (CHO) diet
  vs. low-fat diet
    in NAFLD management, 96–98

Low-CHO diet. See Low-carbohydrate (CHO) diet

Low-fat diet
  vs. low-CHO diet
    in NAFLD management, 96–98

Lysyl oxidase–like-2 inhibitory monoclonal antibody
  in NAFLD management, 84

M

Macronutrients
  in NAFLD management, 96–101
Malnutrition
CLD and, 206–209
described, 205–206
pathogenesis of, 180
prevalence of, 180
Metabolic syndrome
components of, 151
defined, 148
DILI effects of, 165–178. See also Drug-induced liver injury (DILI)
HBV effects of, 165–178. See also Hepatitis B virus (HBV)
HCV effects of, 147–156. See also Hepatitis C virus (HCV)
Metabolism
impaired, 181
Metformin
in NAFLD management, 74–76
Methotrexate
liver injury related to, 173
Methylenetetrahydrofolate reductase polymorphisms in
in obesity-associated NAFLD, 257–258
Micronutrients
in NAFLD management, 101–105
Microsomal triglyceride transport protein polymorphisms in
in obesity-associated NAFLD, 252
Mitochondrial dysfunction
obesity effects on, 48–49

N
NAFLD. See Nonalcoholic fatty liver disease (NAFLD)
NASH. See Nonalcoholic steatohepatitis (NASH)
Nonalcoholic fatty liver disease (NAFLD)
cardiovascular diseases and interactions between, 233–248
FRS in predicting, 243
mechanisms in, 241–243
mortality effects, 235–236
specific events, 236–241
surrogate markers of atherosclerosis, 234–235
in children
evaluation of, 221–223
exercise for, 117–118
functional status of patients with described, 115–117
exercise in optimization of, 113–127
behavioral considerations supporting, 120–123
introduction, 113–114
gut macrobiota and, 62–67
HCC and noncirrhotic liver in, 195–197
HCC and obesity in, 194–195
Nonalcoholic (continued)

macronutrient effects in, 96–101
management of
diet and nutritional intervention in, 91–112
  antioxidants, 101–105
  fiber, 101–105
  introduction, 91–92
  low-CHO diet, 96–98
  macronutrients, 96–101
  micronutrients, 101–105
  practical approach to, 105–106
  weight loss as target of, 92–96
medications in, 73–89. See also specific agents
  antioxidants, 77–80, 101–105
  bile acids and derivatives, 80–81
  drugs modulating RAS, 83–84
  endocannabinoids, 83
  hepatoprotective agents, 77–80
  incretin mimetics, 82
  insulin sensitizers in, 74–77
  introduction, 73–74
  lipid-lowering drugs, 77–80
  lysyl oxidase–like-2 inhibitory monoclonal antibody, 84
  new areas of research related to, 81–84
  obeticholic acid and farnesoid X receptor agonists, 82
  PPAR-α agonists, 83
  PPAR-δ agonists, 82–83
mortality related to, 235–236
obesity-associated, 6–7, 19–31, 59–71
  antibiotics in, 66–67
  in children, 220
    evaluation of, 221–223
clinical correlations in, 24–25
host genetic variants in, 249–267
  genetic association studies, 251
  introduction, 249–251
  polymorphisms in genes influencing lipid metabolism, 254–257
  polymorphisms in genes involved in adipogenesis, appetite regulation, fibrosis, oxidative load, and inflammation, 257–261
  polymorphisms in genes involved in synthesis, storage, and export of hepatic triglyceride, 251–254
  incidence of, 21–22
  introduction, 19–21, 59–60
morbid obesity
  surgical management of, 129–146. See also Bariatric-metabolic (BM) surgery, in
    NAFLD management in morbidly obese patients
    future directions in, 141
    introduction, 129–130
    laparoscopic BM surgery, 130–133
prebiotics in, 66–67
prevalence of, 21–22
probiotics in, 66–67
worldwide differences in, 23–24
obesity-related steatosis and, 34–35
pathophysiological basis of, 62–66
altered bile acid metabolism in, 66
endogenous ethanol in, 66
impaired choline metabolism in, 65–66
innate immunity, TLRs, and inflammasomes in, 64–65
small intestinal bacterial overgrowth and intestinal permeability in, 63–64
surrogate markers of atherosclerosis and, 234–235
Nonalcoholic steatohepatitis (NASH), 35–37

Nutrient(s)
metabolism of
  liver in, 206
poor intake of, 180–181

Nutrition
in children, 219–231
management of, 223–227
in cirrhosis, 179–190. See also Cirrhosis, nutrition in
in CLD, 179–190. See also Chronic liver disease (CLD), nutrition in
  effects of, 205–218. See also Chronic liver disease (CLD)
in NAFLD management, 91–112. See also Nonalcoholic fatty liver disease (NAFLD),
management of, diet and nutritional intervention in

Nutritional assessment, 211
  in cirrhosis and CLD, 181–184

Nutritional status
  assessment of, 211
  poor
    in CLD
      management strategies for, 211–212

O

Obesity
challenges in, 2–3
in children, 219–231. See also Children, obesity in
CLD effects of, 205–218
defined, 1
described, 41–42
DILI effects of, 165–178. See also Drug-induced liver injury (DILI)
gut macrobiota and, 60–62
HBV effects of, 165–178. See also Hepatitis B virus (HBV)
HCC effects of, 160
  in CLD, 197
  in NAFLD, 194–195
HCV effects of, 147–156. See also Hepatitis C virus (HCV)
impact on liver histology, 33–40
incidence of, 41
liver cancer related to, 191–203. See also Liver cancer, obesity and
liver disease related to, 1–18. See also specific diseases, e.g., Nonalcoholic fatty liver
disease (NAFLD), obesity-associated
Obesity (continued)

- cirrhosis, 8
- decompensated liver disease, 8
- HCC, 7–8
- HCV, 7
- introduction, 1–2
- NAFLD, 6–7, 19–31, 59–71, 249–267

- morbid
  - NAFLD and surgical management of, 129–146. See also Nonalcoholic fatty liver disease (NAFLD), obesity-associated, morbid obesity, surgical management of morbidity and mortality related to, 3–4
  - prevalence of, 3
  - treatment of, 8–14
    - bariatric surgery in, 13–14
    - lifestyle-based, 8–10
    - pharmacotherapy in, 10–13

Obeticholic acid and farnesoid X receptor agonists

- in NAFLD management, 82

Orlistat

- in NAFLD management, 79

P

Patatin-like phospholipase domain-containing 3 polymorphisms in
  - in obesity-associated NAFLD, 253

Pentoxifylline

- in NAFLD management, 80

Peroxisome proliferator–activated receptor-alpha polymorphisms in
  - in obesity-associated NAFLD, 254–255

Peroxisome proliferator–activated receptor g coactivator 1-alpha polymorphisms in
  - in obesity-associated NAFLD, 255

Peroxisome proliferator–activated receptor-gamma polymorphisms in
  - in obesity-associated NAFLD, 255

Phosphatidylethanolamine N-methyltransferase polymorphisms in
  - in obesity-associated NAFLD, 252–253

Polyunsaturated fatty acids

- in NAFLD management, 79

PPAR-α/δ agonists

- in NAFLD management, 83

PPAR-δ agonists

- in NAFLD management, 82–83

Prebiotics

- in obesity-associated NAFLD, 66–67

Primary hepatic neoplasms, 38
Probiotics
in obesity-associated NAFLD, 66–67

R
RAS. See Renin-angiotensin system (RAS)
Renin-angiotensin system (RAS)
drugs modulating
in NAFLD management, 83–84

S
Statin(s)
in NAFLD management, 77–78
Steatohepatitis
nonalcoholic, 35–37
Steatosis
effect on liver injury and disease outcomes, 169–170
effect on therapeutic outcomes, 170–171
in HBV
molecular mechanisms and factors associated with, 167–168
prevalence and determinants of, 166–167
HCV and, 150
nonspecific or physiologic, 33–34
obesity-related
NAFLD and, 34–35
Sylbibin
in NAFLD management, 80

T
Thiazolidinediones
in NAFLD management, 76–77
Transforming growth factor beta 1 and angiotensin II
polymorphisms in
in obesity-associated NAFLD, 258–259
Tumor necrosis factor α
polymorphisms in
in obesity-associated NAFLD, 258

U
UDCA. See Ursodeoxycholic acid (UDCA)
Ursodeoxycholic acid (UDCA)
in NAFLD management, 80–81

V
Visceral fat
adipokines and cytokines derived from
obesity effects on, 44–45
Visceral fat composition
   obesity effects on, 42–44
Vitamin E
   in NAFLD management, 79–80

W
Weight loss
   in NAFLD management, 92–96